We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Aging and Heparin-Related Bleeding

Norman R. C. Campbell, MD; Russell D. Hull, MBBS; Rollin Brant, PhD; David B. Hogan, MD; Graham F. Pineo, MD; Gary E. Raskob, MSc
Arch Intern Med. 1996;156(8):857-860. doi:10.1001/archinte.1996.00440080047006.
Text Size: A A A
Published online


Background:  Many studies have suggested that elderly patients are at increased risk of bleeding during heparin therapy.

Objective:  To establish whether the risk of bleeding in the elderly results from concomitant risk factors or is associated with the aging process itself.

Methods:  One hundred ninety-nine patients who presented with proximal deep vein thrombosis were treated with a standard intravenous heparin protocol in a doubleblind, randomized, prospective study. Bleeding complications were monitored. Activated partial thromboplastin times and heparin levels were assessed 4 to 6 hours after a standard intravenous heparin bolus and infusion. Heparin doses and heparin levels were also assessed after stable therapeutic heparin infusion rates were established.

Results:  There was an increase in total and major bleeding complications with aging (P<.05) that was not accounted for by standard risk factors for bleeding. Aging was associated with an increase in heparin levels (r=.239, P=.003) and a tendency for an increase in activated partial thromboplastin time (r=.134, P=.07) after standard heparin doses. Aging was also associated with lower heparin dose requirements (r= /p=m-/.267, P=.003) after therapeutic activated partial thromboplastin times were achieved.

Conclusion:  Aging is a risk for heparin-related bleeding that may be explicable by age-related changes in the pharmacologic characteristics of heparin.(Arch Intern Med. 1996;156:857-860)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

84 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.